Answers are grounded in this paper and cite their sources.
Background For patients with metastatic triple-negative breast cancer (mTNBC) who are not candidates for PD-1/PD-L1 inhibition, first-line systemic therapy has historically relied on single-agent or doublet chemotherapy, with dismal survival and moderate attrition to second line. Antibody–drug conjugates (ADCs) targeting TROP2, including sacituzumab govitecan (SG) and datopotamab deruxtecan (Dato-DXd), have been recently evaluated as first-line therapy in this setting in the phase III ASCENT-03 and TROPION-Breast02 trials, respectively, leading to FDA approval of both agents in 2026. Methods We performed a descriptive comparative analysis of ASCENT-03 and TROPION-Breast02, focusing on trial design, patient selection (including PD-L1 status and disease-free interval [DFI]), chemotherapy backbones, stratification factors, crossover and subsequent therapies, efficacy outcomes (progression-free survival [PFS], overall survival [OS], objective response rate [ORR], duration of response), and safety profiles. Data were extracted from the primary publications and supplementary appendices of ASCENT-03 and TROPION-Breast02. Results Both trials enrolled untreated, locally advanced unresectable or mTNBC for whom immunotherapy was not an option. ASCENT-03 included an almost uniformly PD-L1-negative population (~ 99% CPS <10), whereas TROPION-Breast02 allowed up to ~10% PD-L1-high tumors (CPS ≥10) and stratified by PD-L1 and DFI. SG improved PFS versus chemotherapy in ASCENT-03 (median 9.7 vs 6.9 months; HR 0.62), with similar OS at the interim descriptive analysis (21.5 vs 20.2 months) in the context of extensive crossover. Dato-DXd improved PFS in TROPION-Breast02 of a similar magnitude (10.8 vs 5.6 months; HR 0.57) and demonstrated an OS benefit (23.7 vs 18.7 months; HR 0.79) with no protocol-mandated crossover. ORR was 48% vs 46% (SG vs chemotherapy) in ASCENT-03 and 62.5% vs 29.3% (Dato-DXd vs chemotherapy) in TROPION-Breast02. Interpretation of cross-trial OS/ORR differences should account for population and treatment-context contrasts: both trials largely preceded contemporary early-stage chemo-immunotherapy standards (low prior platinum and PD-1/PD-L1 exposure), and TROPION-Breast02 used predominantly taxane monotherapy in the control arm (83%) with no mandated crossover with relatively limited subsequent ADC use (~ 30% of controls). In TROPION-Breast02, efficacy appeared more favorable in Asian versus non-Asian subgroups, and the trial enrolled a higher proportion of Asian patients than ASCENT-03. Conclusions ASCENT-03 and TROPION-Breast02 together establish TROP2-directed ADCs as an active first-line option for immunotherapy-ineligible mTNBC, consistently outperforming chemotherapy alone in terms of PFS. ASCENT-03 clarifies the value of SG in PD-L1-negative population but, due to extensive crossover not embedded within a formal endpoint, it cannot ultimately inform the question of early versus delayed SG exposure. Both trials in fact are not strategy trials and the speculation on sequencing is overall speculative and non-conclusive. TROPION-Breast02, powered for both PFS and OS and conducted with flexible chemotherapy and subsequent ADC use in a subset of patients in the control arm, provides evidence that first-line Dato-DXd may extend survival in a broader immunotherapy-ineligible population, although the optimal sequencing of TROP2-directed ADCs remains unresolved. Collectively, the evidence reported does more than identify a single “best” ADC, it offers complementary lessons: optimal use of SG and Dato-DXd will depend on patient characteristics, prior therapies, comorbidities, toxicity trade-offs, access to subsequent lines, with evolving real-world data on sequencing still waited to frame, and optimize the post-ADC setting.
No takes yet. Share an insight, caveat, or question.
Sanchez et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: